Diagnosing and treating autoimmune disorders is notoriously difficult due to the wide variability in symptoms, disease progression, and treatment responses. Patients often endure years of uncertainty before receiving an accurate diagnosis. However, autoantibody profiling offers a promising solution.
Circulating autoantibodies target self-antigens and appear early in the disease process—even before symptoms emerge. This makes them powerful biomarkers for disease identification and personalized treatment.
Though a single biomarker may not suffice for precise classification, combining multiple antibody biomarkers into a signature can greatly enhance predictive accuracy.
